ClinicalTrials.gg
Active, not recruitingNCT01522976Updated Nov 18, 2026Results posted

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

A Phase 2 interventional study of Azacitidine and Laboratory Biomarker Analysis in Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1 and Chronic Myelomonocytic Leukemia-2, sponsored by National Cancer Institute (NCI). Active, not recruiting at 294 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies testing azacitidine in Leukemia, Myelomonocytic, Chronic — 3 open to participants now, 8 under way, 1 of them phase 3. Azacitidine · Leukemia, Myelomonocytic, Chronic.

Enrollment
2nd of 37
282 · median 34
Started
2012
with 1 other
Phase 2
16 of 38
1 open now
Registered
17th of 38
by date
Lead sponsor
4 of 38
National Cancer Institute (NCI)

Among the 38 studies testing azacitidine in Leukemia, Myelomonocytic, Chronic, this one is the 2nd largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2012, is one of 16 in phase 2, and was the 17th registered.

Leukemia, Myelomonocytic, Chronic

540 studies on the registry are indexed under Leukemia, Myelomonocytic, Chronic; 68 are open to participants now.

Browse Leukemia, Myelomonocytic, Chronic studies →

Open to participants now

3 of the 38 studies testing azacitidine in Leukemia, Myelomonocytic, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 62 Leukemia, Myelomonocytic, Chronic studies recruiting now, 47 (76%) set no upper age limit and 7 (11%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing azacitidine in Leukemia, Myelomonocytic, Chronic, or all of them as a file.
02

Study summary

This randomized phase II/III trial studies how well azacitidine works with or without lenalidomide or vorinostat in treating patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether azacitidine is more effective with or without lenalidomide or vorinostat in treating myelodysplastic syndromes or chronic myelomonocytic leukemia.

Read the detailed description

PRIMARY OBJECTIVES:

I. To select based on response rate (complete remission, partial remission, or hematologic improvement) either the combination of lenalidomide and azacitidine or the combination of vorinostat and azacitidine for further testing against single-agent azacitidine among patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). (Phase II) II. To compare overall survival between the combination arm selected in the Phase II portion of the trial to single-agent azacitidine among patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). (Phase III)

SECONDARY OBJECTIVES:

I. To estimate relapse-free survival, overall survival and cytogenetic response rate of patients treated on each regimen.

II. To estimate the frequency and severity of toxicities of the three regimens in this patient population.

III. To investigate in a preliminary manner the frequency of subgroups from prestudy cytogenetic studies and correlate these subgroups with clinical outcomes in this patient population.

IV. To collect specimens for banking for use in future research studies.

TERTIARY OBJECTIVES:

I. To evaluate the prevalence of a pre-specified list of molecular lesions (48 total lesions).

II. To assess associations of these lesions with outcomes (response, event-free survival, relapse-free survival, and overall survival).

III. To develop a deoxyribonucleic acid (DNA) methylation biomarker predictive of response to DMTi treatment in MDS.

IV. To harness gene expression profiles as clinical biomarkers of primary resistance to DMTi in MDS.

OUTLINE: Patients are randomized to 1 of 3 treatment arms. In Phase III, patients are randomized to 1 of 2 treatment arms (the combination arm selected in Phase II or the single-agent azacitidine arm).

ARM I: Patients receive azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 or days 1-5 and 8-9, and lenalidomide orally (PO) once daily (QD) on days 1-21.

ARM II: Patients receive azacitidine as in Arm I.

ARM III: Patients receive azacitidine as in Arm I and vorinostat PO twice daily (BID) on days 3-9.

In all arms, treatment repeats every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for up to 5 years.

03

Conditions studied

  • Chronic Myelomonocytic Leukemia
  • Chronic Myelomonocytic Leukemia-1
  • Chronic Myelomonocytic Leukemia-2
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndrome With Excess Blasts
  • Myelodysplastic Syndrome With Excess Blasts-1
  • Myelodysplastic Syndrome/Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must have morphologically confirmed diagnosis of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) based on one of the following:

    • French-American-British (FAB) classifications:

      • anemia with excess blasts (RAEB - defined as having 5-20% myeloblasts in the bone marrow)
      • Chronic myelomonocytic leukemia (CMML) with 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood
    • World Health Organization (WHO) classifications:

      • Refractory anemia with excess blasts-1 (RAEB-1 - defined as having 5-9% myeloblasts in the bone marrow)
      • Refractory anemia with excess blasts-2 (RAEB-2 - defined as having 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood)
      • Chronic myelomonocytic leukemia-1 (CMML-1 - defined as having \< 10% myeloblasts in the bone marrow and/or \< 5% blasts in the blood)
      • Chronic myelomonocytic leukemia-2 (CMML-2 - defined as having 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood) OR
    • International prognostic score (IPSS) of intermediate 2 (1.5-2.0 points) or high (>= 2.5 points); a score of intermediate 1 (0.5-1.0 points) is only allowable in the setting of >= 5% myeloblasts
    • NOTE: Patients with acute myeloid leukemia (AML) are not eligible
    • Procedures to obtain specimens for establishing baseline disease must be done within 30 days prior to registration
  • Patients must not have received lenalidomide, azacitidine, vorinostat, or decitabine as treatment previously; any hematopoietic growth factors must be stopped for at least 14 days prior to registration; patients may have received low-dose cytarabine for MDS treatment previously, but they must have discontinued its use for at least 28 days prior to registration; patients may have received prior hydroxyurea per CMML treatment previously, but they must have discontinued its use for at least 7 days prior to registration; these patients will not be eligible if white blood cell (WBC) > 30,000/mm\^3
  • Patients must not have received radiation therapy, chemotherapy, or cytotoxic therapy to treat conditions other than MDS within 12 months prior to registration
  • Patients must not have undergone prior allogeneic stem cell or bone marrow transplantation at any time; patients that have undergone an stem cell transplant are eligible
  • Patients must not have used or be using histone deacetylase (HDAC) inhibitor agents for anticancer treatment
  • Patients may not have received agents such as valproic acid for epilepsy within 30 days prior to registration
  • Patients must have Zubrod performance status of 0-2
  • Patients must not have any pre-existing neurotoxicity/neuropathy of >= grade 2 according to the National Cancer Institute (NCI) Common Toxicity Criteria version 4.0, or prior >= grade 3 allergic reaction/ or rash to thalidomide, that has not resolved to \< grade 2
  • Patients must not have any serious medical condition, laboratory abnormality, or psychiatric illness that, in the view of the treating physician, would place the participant at an unacceptable risk if he or she were to participate in the study or would prevent that person from giving
  • Patients must not have history of thromboembolic event or other condition requiring current use of anticoagulation with Coumadin (warfarin) or low molecular-weight heparin
  • Patients must not have known or suspected hypersensitivity to mannitol
  • Patients must receive a 12-lead (EKG), chest x-ray or computed tomography (CT) scan, serum creatinine, complete metabolic panel including serum glutamic oxaloacetic transaminase () or serum glutamate pyruvate transaminase (SGPT), electrolytes, and testing within 28 days prior to registration in order to establish baseline measurements; questions regarding patient safety in regards to results of these tests should be directed to the study chair
  • Females of (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to registration; FCBP must agree to have a second pregnancy test within 24 hours prior to starting cycle 1 if randomized to receive lenalidomide

    • Further, patients commit to the following if they are randomized to receive lenalidomide: FCBP must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of : one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before starting lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy; a FCBP is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months); all patients must be counseled by a trained counselor every 28 days about pregnancy precautions and risks of fetal exposure
    • NOTE: Patients not randomized to receive lenalidomide will not be required to undergo serial pregnancy testing or lenalidomide counseling after registration
  • No prior is allowed except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for three years
  • Cytogenetics requirements:

    • Southwestern Oncology Group (SWOG) (and other sites not affiliated with Alliance or [ECOG]-American College of Radiology Imaging Network [ACRIN]): Pretreatment cytogenetics must be performed on all patients; collection of pretreatment specimens must be completed within 30 days prior to registration to S1117; specimens must be submitted to the site's preferred Clinical Laboratory Improvement Amendments (CLIA)-approved cytogenetics laboratory; reports of the results must be submitted as described; note that cytogenetics are required at other timepoints; NOTE: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) sites may submit specimens to College of American Pathologists (CAP) or Ontario Laboratory Accreditation (OLA)-approved laboratories providing the lab is licensed to perform fluorescent in situ hybridization (FISH) analysis
    • Alliance: Alliance patients must enroll on Cancer and Leukemia Group B (CALGB) 8461, the cytogenetics protocol; CALGB 8461 provides sample procurement and submission instructions to Alliance-approved institutional cytogeneticists; note that cytogenetics are required at other timepoints
    • ECOG-ACRIN: Pretreatment cytogenetics must be performed on all patients; collection of pretreatment specimens must be completed within 30 days prior to registration to S1117; specimens must be submitted to the site's preferred CLIA-approved cytogenetics laboratory; karyotypes and reports must be submitted for review to the Mayo Clinic Cytogenetics Laboratory in Rochester; note that cytogenetics testing is required at other timepoints
  • Banking requirements:

    • SWOG, Alliance and ECOG-ACRIN (and other sites not affiliated with NCIC CTG): Patients must be offered participation in specimen banking; with patient consent, specimens must be submitted as outlined
    • Alliance: (Temporarily Closed 2/28/14): As of February 28, 2014, CALGB 9665 has been temporarily closed, so Alliance patients under consideration for S1117 are NOT to be registered to CALGB 9665 and no specimens for patients enrolled after February 28, 2014 are to be submitted via this ancillary study; these patients should submit specimens per SWOG instructions; patients already enrolled on CALGB 9665 should continue to submit specimens per instructions in CALGB 9665
    • NCIC CTG: NCIC CTG patients must be offered participation in specimen submission and banking; with patient consent, specimens must be submitted as outlined
  • All patients or their legally authorized representative must be informed of the nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
  • As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
282 participants (actual)

Study arms

  • Experimental
    Arm I (azacitidine and lenalidomide)

    Patients receive azacitidine SC or IV on days 1-7 or days 1-5 and 8-9, and lenalidomide PO QD on days 1-21. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.

    Drug: Azacitidine · Other: Laboratory Biomarker Analysis · Drug: Lenalidomide

  • Experimental
    Arm II (azacitidine)

    Patients receive azacitidine as in Arm I. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.

    Drug: Azacitidine · Other: Laboratory Biomarker Analysis

  • Experimental
    Arm III (azacitidine and vorinostat)

    Patients receive azacitidine as in Arm I and vorinostat PO BID on days 3-9. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.

    Drug: Azacitidine · Other: Laboratory Biomarker Analysis · Drug: Vorinostat

Interventions

  • Given SC or IV

    Also known as: 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • Given PO

    Also known as: CC 5013, CC-5013, CC5013, CDC 501, Revlimid

  • Given PO

    Also known as: L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza

06

What researchers measure

Primary outcomes

  1. Response Rate (Phase II)

    A response is any of complete hematological remission, partial remission, or hematologic improvement.

    Time frame: Up to 5 years

  2. Overall Survival (Phase III)

    OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow-up for patients last known to be alive is censored at the date of last contact. Stratified Cox regression models will be used to compare OS of the combination arm selected in the Phase II portion of the trial to OS of the single-agent azacitidine arm.

    Time frame: Up to 5 years

Secondary outcomes

  1. Relapse-free Survival

    RFS is calculated for patients who have achieved a response. RFS will be measured from the date of response to the date of first documentation of relapse from response (as defined in the primary objective), or death due to any cause. The follow-up for patients last known to be alive and without report of relapse is censored at the date of last contact. RFS will be estimated for each of the three arms using the Kaplan-Meier method.

    Time frame: Up to 5 years

  2. Overall Survival

    OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow- up for patients last known to be alive is censored at the date of last contact. OS will be estimated for each of the three arms using the Kaplan-Meier method.

    Time frame: Up to 5 years

  3. Pre-study Cytogenetic Abnormalities

    Cytogenetic risk group is used to identify cytogenetic abnormalities.

    Time frame: Up to 5 years

  4. Toxicity Rate

    Adverse events that are possibly, probably or definitely related to study drug are reported.

    Time frame: Up to 5 years

07

Results

Posted Mar 22, 2016

Participant flow

Participant flow — Overall Study
MilestoneArm 1: Azacitidine/LenalidomideArm 2: AzacitidineArm 3: Azacitidine/Vorinostat
Started979293
Completed000
Not completed979293
Withdrew: Ineligible401
Withdrew: Death762
Withdrew: Still on treatment996
Withdrew: Disease progression283025
Withdrew: Adverse event17718
Withdrew: Refusal unrelated to adverse event101314
Withdrew: Not protocol specified222727

Outcome measures

PrimaryResponse Rate (Phase II)

A response is any of complete hematological remission, partial remission, or hematologic improvement.

Time frame:
Up to 5 years
Reported as:
Number · percentage of patients having a response
Response Rate (Phase II)
percentage of patients having a responseArm 1: Azacitidine/LenalidomideArm 2: AzacitidineArm 3: Azacitidine/Vorinostat
Response Rate (Phase II)49 (39 to 60)38 (28 to 49)27 (18 to 37)
PrimaryOverall Survival (Phase III)

OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow-up for patients last known to be alive is censored at the date of last contact. Stratified Cox regression models will be used to compare OS of the combination arm selected in the Phase II portion of the trial to OS of the single-agent azacitidine arm.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryRelapse-free Survival

RFS is calculated for patients who have achieved a response. RFS will be measured from the date of response to the date of first documentation of relapse from response (as defined in the primary objective), or death due to any cause. The follow-up for patients last known to be alive and without report of relapse is censored at the date of last contact. RFS will be estimated for each of the three arms using the Kaplan-Meier method.

Time frame:
Up to 5 years
Reported as:
Median · Days
Relapse-free Survival
DaysArm 1: Azacitidine/LenalidomideArm 2: AzacitidineArm 3: Azacitidine/Vorinostat
Relapse-free Survival435 (237 to 546)311 (182 to 640)455 (197 to NA)
SecondaryOverall Survival

OS is calculated for all patients from the date of initial registration to date of death due to any cause. The follow- up for patients last known to be alive is censored at the date of last contact. OS will be estimated for each of the three arms using the Kaplan-Meier method.

Time frame:
Up to 5 years
Reported as:
Median · Days
Overall Survival
DaysArm 1: Azacitidine/LenalidomideArm 2: AzacitidineArm 3: Azacitidine/Vorinostat
Overall Survival588 (426 to 737)449 (356 to 603)527 (392 to 852)
SecondaryPre-study Cytogenetic Abnormalities

Cytogenetic risk group is used to identify cytogenetic abnormalities.

Time frame:
Up to 5 years
Reported as:
Number · participants
Pre-study Cytogenetic Abnormalities
participantsArm 1: Azacitidine/LenalidomideArm 2: AzacitidineArm 3: Azacitidine/Vorinostat
Good/very good352934
Intermediate131618
Poor8108
Very poor232319
Missing141413
SecondaryToxicity Rate

Adverse events that are possibly, probably or definitely related to study drug are reported.

Time frame:
Up to 5 years
Reported as:
Number · Participants
Toxicity Rate
ParticipantsArm 1: Azacitidine/LenalidomideArm 2: AzacitidineArm 3: Azacitidine/Vorinostat
Abdominal infection100
Abdominal pain103
Acute kidney injury001
Adult respiratory distress syndrome100
Alanine aminotransferase increased005
Anemia483744
Anorectal infection001
Anorexia403
Apnea001
Ascites101
Aspartate aminotransferase increased003
Ataxia001
Back pain100
Blood and lymphatic system disorders - Other021
Blood bilirubin increased003
Bronchial infection001
CD4 lymphocytes decreased100
Cardiac arrest100
Catheter related infection121
Cecal infection001
Cholecystitis001
Colitis001
Confusion001
Constipation211
Creatinine increased200
Dehydration513
Delirium001
Diarrhea503
Dizziness100
Dyspnea423
Epistaxis001
Esophageal pain001
Esophagitis100
Fall001
Fatigue9614
Febrile neutropenia161113
Fever002
Flushing001
Gastric hemorrhage001
Gastrointestinal pain101
General disorders and admin site conditions-Other100
Generalized muscle weakness313
Hallucinations001
Headache001
Heart failure001
Hematoma001
Hematuria102
Hyperglycemia112
Hypernatremia010
Hypertension102
Hyperuricemia001
Hypoalbuminemia300
Hypokalemia401
Hypomagnesemia100
Hyponatremia514
Hypophosphatemia102
Hypotension403
Hypoxia001
Infections and infestations - Other, specify425
Intracranial hemorrhage100
Investigations - Other, specify100
Leukocytosis010
Lower gastrointestinal hemorrhage002
Lung infection412
Lymphocyte count decreased1493
Lymphocyte count increased011
Mucosal infection001
Mucositis oral100
Nausea122
Neutrophil count decreased694863
Pain100
Papulopustular rash100
Pericardial effusion100
Platelet count decreased614664
Pneumonitis001
Pruritus100
Pulmonary edema001
Purpura100
Rash maculo-papular1331
Renal and urinary disorders - Other, specify001
Respiratory failure001
Sepsis423
Sinus bradycardia100
Skin infection312
Soft tissue infection110
Sudden death NOS010
Syncope204
Thromboembolic event101
Tooth infection001
Upper gastrointestinal hemorrhage001
Upper respiratory infection010
Urinary tract infection111
Vascular disorders - Other, specify001
Vomiting111
Weight loss100
White blood cell decreased483444

Adverse events

Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: Azacitidine/Lenalidomide—37/89 (41.6%)88/89 (98.9%)
Arm 2: Azacitidine—8/91 (8.8%)89/91 (97.8%)
Arm 3: Azacitidine/Vorinostat—47/91 (51.6%)91/91 (100%)
Most frequent serious events
Showing 10 of 118
Most frequent serious events
EventArm 1: Azacitidine/LenalidomideArm 2: AzacitidineArm 3: Azacitidine/Vorinostat
Infections and infestations-OtherInfections and infestations4/890/918/91
Platelet count decreasedInvestigations7/890/918/91
AnemiaBlood and lymphatic system disorders6/890/916/91
Febrile neutropeniaBlood and lymphatic system disorders6/891/912/91
DyspneaRespiratory, thoracic and mediastinal disorders6/890/912/91
FeverGeneral disorders1/890/916/91
Lung infectionInfections and infestations5/890/914/91
Abdominal painGastrointestinal disorders0/890/915/91
Atrial fibrillationCardiac disorders4/890/910/91
SepsisInfections and infestations4/892/914/91
Most frequent other events
Showing 10 of 97
Most frequent other events
EventArm 1: Azacitidine/LenalidomideArm 2: AzacitidineArm 3: Azacitidine/Vorinostat
Platelet count decreasedInvestigations78/8968/9169/91
Neutrophil count decreasedInvestigations77/8958/9173/91
AnemiaBlood and lymphatic system disorders76/8971/9172/91
FatigueGeneral disorders74/8969/9174/91
White blood cell decreasedInvestigations66/8952/9160/91
NauseaGastrointestinal disorders38/8942/9161/91
ConstipationGastrointestinal disorders49/8954/9144/91
DiarrheaGastrointestinal disorders42/8923/9153/91
Rash maculo-papularSkin and subcutaneous tissue disorders46/8920/9116/91
AnorexiaMetabolism and nutrition disorders39/8931/9145/91

Baseline characteristics

Analysis includes eligible patients only.

Age, Continuous
Age, Continuous(years)Arm 1: Azacitidine/LenalidomideArm 2: AzacitidineArm 3: Azacitidine/VorinostatTotal
Median70.81 (51.29 to 86.68)69.67 (42.69 to 88.96)70.36 (28.69 to 93.01)70.18 (28.69 to 93.01)
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Azacitidine/LenalidomideArm 2: AzacitidineArm 3: Azacitidine/VorinostatTotal
Female32312285
Male616170192
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: Azacitidine/LenalidomideArm 2: AzacitidineArm 3: Azacitidine/VorinostatTotal
American Indian or Alaska Native1012
Asian1427
Native Hawaiian or Other Pacific Islander0011
Black or African American2349
White868083249
More than one race0000
Unknown or Not Reported3519
08

Study locations

294 sites

Showing the first 100 of 294 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Statler A, Othus M, Erba HP, Chauncey TR, Radich JP, Coutre S, Advani A, Nand S, Ravandi F, Mukherjee S, Sekeres MA. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood. 2018 Jun 21;131(25):2782-2788. doi: 10.1182/blood-2018-01-826693. Epub 2018 Apr 4. PubMed 29618479 ↗
10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Jun 2015, 39 months.

Results were first posted in Mar 2016, 9 months after primary completion.

Of 62 non-industry phase 2 interventional studies under Leukemia, Myelomonocytic, Chronic, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 111. This study's 39 months is below that.

Counting every sponsor, half of 69 studies reached it within 68 months; a quarter within 46 and three quarters within 110.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2012
First posted
Feb 1, 2012
StartActual
Mar 1, 2012
Primary completionActual
Jun 1, 2015
CompletionEst.
Mar 31, 2027
Results first posted
Mar 22, 2016
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: site details
1 update, last Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Minor edits only
    + 1 other change: site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01522976
Responsible party
Sponsor
First posted
Feb 1, 2012
Start date
Mar 1, 2012
Primary completion
Jun 1, 2015
Completion
Mar 31, 2027 (estimated)
Results posted
Mar 22, 2016
Last update
Nov 18, 2026

Study contacts

Mikkael A Sekeres
principal investigator · SWOG Cancer Research Network

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion